Advertisement

Advertisement

colorectal cancer
hepatobiliary cancer

Liver-Sparing Surgery Associated With Higher Survival Rates in Cancer Patients

According to researchers at Memorial Sloan Kettering Cancer Center (MSKCC), hepatic parenchymal preservation, in which a surgeon removes less than a lobe of the liver in a patient undergoing an operation for liver cancer, is associated with lower mortality and complication rates. Their study...

hepatobiliary cancer
supportive care

Urea-Based Cream Prevents Sorafenib-Associated Hand-Foot Skin Reactions in Chinese Patients With Advanced Hepatocellular Carcinoma

In a Chinese study reported in the Journal of Clinical Oncology, Ren et al found that prophylactic use of urea-based cream reduced the incidence of sorafenib (Nexavar)–associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. Urea-based creams are used to treat...

hepatobiliary cancer

No Survival Benefit of Adding Erlotinib to Sorafenib in Advanced Hepatocelluar Carcinoma

In the phase III SEARCH trial reported in the Journal of Clinical Oncology, Zhu et al found no overall survival benefit of adding erlotinib (Tarceva) to sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma. Study Details In this double-blind trial conducted in 26 countries in...

hepatobiliary cancer
pancreatic cancer

Two Combination Studies Demonstrate Safety and Survival Benefit for VT-122 in Liver and Pancreatic Cancers

The immunooncology company Vicus Therapeutics announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both ...

hepatobiliary cancer

Diabetes Increases Risk of Hepatocellular Carcinoma in All Racial/Ethnic Groups

In a study in the Multiethnic Cohort (composed of men and women from California and Hawaii) reported in the Journal of the National Cancer Institute, Setiawan et al found that diabetes was associated with increased risk of hepatocellular carcinoma in all racial/ethnic groups, with risk being...

hepatobiliary cancer

No Overall Survival Difference for Linifanib vs Sorafenib in Advanced Hepatocellular Carcinoma

In a phase III trial reported in the Journal of Clinical Oncology, Cainap et al found that treatment with linifanib, an ATP-competitive inhibitor of VEGF and PDGF receptor tyrosine kinases, did not improve overall survival compared with sorafenib (Nexavar) treatment in patients with advanced...

hepatobiliary cancer
pancreatic cancer

Regional Hepatopancreaticobiliary Surgical Program Improves Care in VA System

In a retrospective cohort study reported in JAMA Surgery, Lau et al found that implementation of a multidisciplinary hepatopancreaticobiliary surgical program in a Veterans Affairs (VA) health-care region resulted in improved care and outcomes. The study involved analysis of practices and outcomes ...

hepatobiliary cancer

Phase II Trial Shows Overall Survival Benefit With VT-122 Plus Sorafenib in Advanced Hepatocellular Carcinoma

The investigational agent VT-122 appeared to benefit survival when combined with sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma, according to data presented at the 8th Annual International Liver Cancer Association Conference in Kyoto, Japan. Researchers reported an 11-month...

hepatobiliary cancer

Patients With Peritoneal Hepatocellular Carcinoma May Benefit From Cytoreductive Surgery With or Without Intraperitoneal Chemotherapy

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy extended survival over systemic therapy alone in well-selected candidates with peritoneal hepatocellular carcinoma, according to the results of a small retrospective trial reported by Tabrizian et al in the Journal of...

hepatobiliary cancer

Similar 30-Day Outcomes With Laparoscopic vs Open Partial Hepatectomy in Single-Center Experience

In a single-center retrospective matched case-control study reported in JAMA Surgery, Franken et al found no significant differences in 30-day morbidity or mortality, positive margin status, major complications, hospital stay, or readmission rates for laparoscopic vs open partial hepatic resection...

hepatobiliary cancer
issues in oncology

Scientists Pinpoint Gene Likely to Promote Childhood Cancers

Researchers at the Children’s Medical Center Research Institute at UT Southwestern (CRI) have identified a gene that contributes to the development of several childhood cancers, in a study conducted in mouse models. If the findings prove to be applicable to humans, the research could...

hepatobiliary cancer

No Survival Benefit With Everolimus After Failure of Sorafenib in Advanced Hepatocellular Carcinoma

The multikinase inhibitor sorafenib (Nexavar) is the only effective systemic treatment available in advanced hepatocellular carcinoma. In the phase III EVOLVE-1 trial reported in JAMA, Zhu et al found no survival benefit from treatment with the mTOR inhibitor everolimus (Afinitor) after sorafenib...

hepatobiliary cancer

FDA Grants Orphan Drug Designation to ENMD-2076 for Hepatocellular Carcinoma

CASI Pharmaceuticals, Inc, announced that its investigational agent ENMD-2076 has received orphan drug designation from the U.S. Food & Drug Administration (FDA) for the treatment of hepatocellular carcinoma. ENMD-2076 is an orally active Aurora A/angiogenic kinase inhibitor with a unique...

hepatobiliary cancer

No Apparent Benefit of Adding Cetuximab to Gemcitabine Plus Oxaliplatin in Advanced Biliary Tract Cancer

Gemcitabine plus a platinum agent is standard treatment in advanced biliary cancer. In the phase II open-label noncomparative BINGO trial, reported in The Lancet Oncology, Malka et al found no apparent benefit of adding the EGFR inhibitor cetuximab (Erbitux) to gemcitabine/oxaliplatin in first-line ...

hepatobiliary cancer

More Toxicity Associated With Addition of Sorafenib to Yttrium-90 Radioembolization Prior to Liver Transplantation

The addition of sorafenib (Nexavar) to yttrium-90 radioembolization was associated with higher rates of biliary complications and potentially more acute rejections prior to transplantation in patients with hepatocellular carcinoma, according to the results of a prospective randomized pilot study....

hepatobiliary cancer

Insulin-Like Growth Factor-1 Score Improves Assessment of Prognosis in Hepatocellular Carcinoma

In a study reported in the Journal of the National Cancer Institute, Kaseb et al developed a plasma insulin-like growth factor 1 (IGF-1)–based score for hepatic reserve in hepatocellular carcinoma and compared its predictive ability with that of the Child-Turcotte-Pugh (CTP) score in two...

hepatobiliary cancer

Tumor Factors Associated With Poorer Overall Survival in Patients With Intrahepatic Cholangiocarcinoma Undergoing Curative Intent Surgery

There are limited data on outcomes after surgery for intrahepatic cholangiocarcinoma. In a systematic review and meta-analysis reported in JAMA Surgery, Mavros et al found that tumor characteristics are the primary predictors of survival after curative intent surgery, indicating the need for...

hepatobiliary cancer

High Preoperative Hepatitis B Surface Antigen Level Predicts Hepatocellular Carcinoma Recurrence in Patients With Low HBV DNA

In a Chinese study reported in JAMA Surgery, Huang et al found that preoperative elevated hepatitis B virus (HBV) surface antigen (HBsAg) level is an independent risk factor for hepatocellular carcinoma recurrence and mortality in patients with low HBV DNA levels undergoing hepatic resection....

hepatobiliary cancer

FDA Approves Ethiodized Oil Injection for Imaging of Tumors in Adults With Known Hepatocellular Carcinoma

The U.S. Food and Drug Administration has approved ethiodized oil injection (Lipiodol) for selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma. The agent received orphan drug designation for management of patients with known hepatocellular carcinoma ...

hepatobiliary cancer

Three-Dimensional MRI Scans May Offer More Accurate Way to Predict Survival After Chemotherapy for Liver Tumors

In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized three-dimensional (3D) MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy is working. The investigators said ...

hepatobiliary cancer

Poorer Overall Survival With Sunitinib vs Sorafenib in Advanced Hepatocellular Cancer

In an open-label phase III superiority/noninferiority trial reported in Journal of Clinical Oncology by Ann-Lii Cheng, MD, of National Taiwan University Hospital in Taipei, sunitinib (Sutent) was associated with significantly poorer overall survival compared with sorafenib (Nexavar) in a population ...

hepatobiliary cancer

Antiviral Treatment Improves Recurrence-Free and Overall Survival in HBV-Related Hepatocellular Carcinoma

Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma have poor postoperative prognosis. In a study reported in Journal of Clinical Oncology, Jianhua Yin, MD, of the Second Military Medical University in Shanghai, and colleagues assessed the effects of nucleotide/nucleoside analog...

hepatobiliary cancer

Survival Trend With Palliative FOLFOX4 vs Doxorubicin in Asian Patients With Advanced Hepatocellular Carcinoma

In a study reported in Journal of Clinical Oncology, Shukui Qin, MD, of People’s Liberation Army Cancer Centre, Bayi Hospital, in Nanjing, and colleagues compared FOLFOX4 (infusional fluorouracil [5-FU], leucovorin, and oxaliplatin) with doxorubicin as palliative chemotherapy in patients with ...

hepatobiliary cancer

No Overall Survival Benefit With Brivanib in Advanced Hepatocellular Carcinoma Patients After Sorafenib Failure or Intolerance

The investigational agent brivanib is a selective dual inhibitor of VEGF and fibroblast growth factor receptors, both implicated in hepatocellular carcinoma. In a trial (BRISK-PS) reported in Journal of Clinical Oncology, Josep M. Llovet, MD, of the Icahn School of Medicine at Mount Sinai in New...

hepatobiliary cancer

First-Line Brivanib Not Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma

The investigational drug brivanib is a dual inhibitor of VEGF and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. In a noninferiority trial (BRISK-FL) reported in Journal of Clinical Oncology, Philip J. Johnson, MD, of the Institute of Translational Medicine,...

Advertisement

Advertisement

;
Advertisement